Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

Author's Avatar
Nov 10, 2021

Enrollment of first 20 patients of the Company's Phase 2 AML trial anticipated in Q4 2021

Topline readout of Group 2 active disease anticipated in Q1 2022

Company to host year-end conference call and webcast in Q1 2022

PR Newswire